Almirall SA
F:E2Z

Watchlist Manager
Almirall SA Logo
Almirall SA
F:E2Z
Watchlist
Price: 12.9 EUR 0.31%
Market Cap: 2.8B EUR

Gross Margin
Almirall SA

73.7%
Current
74%
Average
48.6%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.7%
=
Gross Profit
1.2B
/
Revenue
1.6B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
ES
Almirall SA
MAD:ALM
2.8B EUR
74%
US
Eli Lilly and Co
NYSE:LLY
1T USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
492.8B USD
68%
CH
Roche Holding AG
SIX:ROG
266.1B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
218.6B GBP
82%
CH
Novartis AG
SIX:NOVN
216.6B CHF
76%
US
Merck & Co Inc
NYSE:MRK
270.8B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
82%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
68%
US
Pfizer Inc
NYSE:PFE
144.6B USD
75%
No Stocks Found

Almirall SA
Glance View

Market Cap
2.8B EUR
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

E2Z Intrinsic Value
13.33 EUR
Undervaluation 3%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.7%
=
Gross Profit
1.2B
/
Revenue
1.6B
What is the Gross Margin of Almirall SA?

Based on Almirall SA's most recent financial statements, the company has Gross Margin of 73.7%.

Back to Top